BNP PARIBAS ARBITRAGE/CALL/BIONTECH ADR/120/0.1/20.12.24 Share Price

Warrant

P1ZPZ3

NLBNPIT1ZPZ3

Real-time Borsa Italiana 09:52:44 28/06/2024 BST
0.105 EUR +1.45% Intraday chart for BNP PARIBAS ARBITRAGE/CALL/BIONTECH ADR/120/0.1/20.12.24
Current month-82.37%
1 month-80.29%
Date Price Change
28/06/24 0.105 +1.45%
27/06/24 0.1035 -16.53%
26/06/24 0.124 -20.26%
25/06/24 0.1555 -18.16%
24/06/24 0.19 +10.79%

Real-time Borsa Italiana

Last update June 28, 2024 at 09:52 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying BIONTECH SE
IssuerLogo Issuer BNP Paribas BNP Paribas
P1ZPZ3
ISINNLBNPIT1ZPZ3
Date issued 20/02/2024
Strike 120 $
Maturity 20/12/2024 (176 Days)
Parity 10 : 1
Emission price-
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.868
Lowest since issue 0.101
Delta0.12x
Omega 8.190
Premium50.7x
Gearing70.73x
Moneyness 0.6698
Difference Strike 39.62 $
Difference Strike %+33.02%
Spread 0.0785
Spread %53.95%
Theoretical value 0.1063
Implied Volatility 40.48 %
Total Loss Probability 93.01 %
Intrinsic value 0.000000
Present value 0.1063
Break even 121.14 €
Theta-0.01x
Vega0.01x
Rho0x

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
75.08 EUR
Average target price
103.5 EUR
Spread / Average Target
+37.88%
Consensus
  1. Stock Market
  2. Warrants
  3. P1ZPZ3 Warrant